
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:publisher>Academic Press</dc:publisher>
  <dc:rights>All rights reserved</dc:rights>
  <dc:title xml:lang="eng">Synthesis and cytotoxic evaluation of pyrido-dipyrimidine derivatives: Mechanism of action, DNA and HSA binding studies</dc:title>
  <dc:creator id="https://orcid.org/0009-0005-8856-2079">Milović, Lazar</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-9178-9200">Stanojković, Tatjana</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-5571-6880">Jeremić, Svetlana</dc:creator>
  <dc:creator id="https://orcid.org/0009-0009-5626-0526">Petrović, Maja</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-3854-9659">Marković, Milica</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-8731-3605">Rilak Simović, Ana</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-2295-9410">Janković, Nenad</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-2543-0838">Grozdić, Nađa</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-3901-6133">Đorović Jovanović, Jelena</dc:creator>
  <dc:identifier>https://phaidrabg.bg.ac.rs/o:38559</dc:identifier>
  <dc:identifier>doi:10.1016/j.bioorg.2026.109740</dc:identifier>
  <dc:identifier>ISSN: 0045-2068</dc:identifier>
  <dc:date>2026</dc:date>
  <dc:subject xml:lang="eng">Pyrido-dipyrimidines; Cytotoxicity; DNA binding; HSA interaction; Molecular docking</dc:subject>
  <dc:format>application/pdf</dc:format>
  <dc:format>8722927 bytes</dc:format>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:description xml:lang="eng">Abstract: This study presents the synthesis of a novel series of
pyrido[2,3-d:6,5-d’]dipyrimidine derivatives (4a-v) via an
‘on-water’ multicomponent reaction, utilizing
thiobarbituric acid, diverse aldehydes, and amines at
room temperature. The compounds were evaluated for
cytotoxic activity against human cancer cell lines (HeLa,
K562, LS174, A549) and normal fibroblasts (MRC-5) using
MTT assays. Notable potency was observed against HeLa
and K562 cells, with IC50 values ranging from 9.82 to
192.47 μM. Compound 4k exhibited the strongest
activity against HeLa (IC50 = 9.82 ± 1.07 μM) with a
selectivity index (SI) &gt;12, while 4u was most effective
against K562 (IC50 = 17.36 ± 1.39 μM, SI &gt;9). LS174 and
A549 showed limited sensitivity. Structure-activity
relationship (SAR) analysis revealed that para-
hydroxyphenyl substituents at position 5 and
thiocarbonyl groups enhanced cytotoxicity, particularly
against leukemia cells, via improved hydrogen bonding
and target affinity. Mechanistic studies on 4k and 4u
focused on DNA and human serum albumin (HSA)
interactions. UV–Vis and fluorescence spectroscopy,
including ethidium bromide displacement and viscosity
measurements, indicated minor groove binding to CT-
DNA (Kb ~ 104 M–1; KSV ~ 104 M–1) with partial intercalation.
HSA binding occurred via static quenching at sites I and II
Državni univerzitet u Novom Pazaru
(KSV ~ 105 M–1; Kb ~105 M–1), confirmed by competitive
assays with Eosin Y and ibuprofen. Cell cycle analysis and
AO/EB staining demonstrated apoptosis induction, with
increased subG1 populations. Caspase assays showed 4k
activated both intrinsic (caspase-9) and extrinsic
(caspase-8) pathways in HeLa cells, leading to caspase-3
execution; 4u induced caspase-independent apoptosis in
K562. Molecular docking and dynamics simulations
supported minor groove DNA preference and HSA site
I/II binding, with stable complexes (ΔGbind ≤ –8 kcal/mol).
RMSD, RMSF, and Rg analyses affirmed structural
integrity. These derivatives emerge as promising
selective anticancer agents targeting DNA and apoptosis,
warranting further optimization and in vivo studies</dc:description>
  <dc:language>eng</dc:language>
  <dc:source>Bioorganic Chemistry</dc:source>
  <dc:source>startpage: 109740</dc:source>
  <dc:source>endpage: 109740</dc:source>
</oai_dc:dc>
